Enhancement by PL 14736 of granulation and collagen organization in healing wounds and the potential role of egr-1 expression

Pentadecapeptide BPC 157 (PL 14736) improves ligament healing in the rat

“…Under the most severe conditions of transected ligament, with BPC 157 mg-ng-regimens given alone intraperitoneally, per-orally and topically, dose-regimens and application methods that had been successfully used before [1][2][3][4][5][6][7][8][9][10][11][12] and in time, the healing process on an acute ligament injury may convert rapidly from a failure to a success and all healing improvements. Function in either condition, normal (walking rats) and stressed (running rats), biomechanic, macro/microscopy were noted superior as before [1][2][3][4][5][6][7][8][9][10][11][12] in tendon studies 1,2,10 and other wound studies, 4,9,10,12 , not species related.…”

“…Function in either condition, normal (walking rats) and stressed (running rats), biomechanic, macro/microscopy were noted superior as before [1][2][3][4][5][6][7][8][9][10][11][12] in tendon studies 1,2,10 and other wound studies, 4,9,10,12 , not species related. This may be a wound healing (not found with standard peptide factors 3,16,17 ) more apt to predispose the ligament to improved healing course after transection.…”

“…The use of the injured leg, improved motor function, lacking postinjury contracture and no valgus instability so far not demonstrated in peptides-ligament healing studies thus apparent function recovery obviously support the regeneration, not impeded by connective tissue, with constantly reestablished damaged cytoarchitecture in ligament healing after transection. Consistently, it was more effective than standard agents (i.e., silver sulfadiazine 1% cream, becaplermin gel (platelet-derived growth factor, PDGF-BB, Regranex, a standard therapy for diabetic foot ulcers PDGF)) in the healing of severe burn injury, diabetic wounds and angiogenesis induction, [1][2][3][4][5][6][7][8][9][10][11][12] likely by upregulating vascular endothelial growth factor (VEGF) expression. 23 Very recently in transected muscle and tendon it seems that the initial angiogenesis phase followed by accelerated VEGF, CD34 and FVIII expression gives way to an increased healing rate since there is no direct angiogenic effect of BPC 157 on cell cultures.…”

“…We introduced intraperitoneal, per-oral (in drinking water) and topical (thin cream layer) peptide therapy always given alone, without a carrier, using stable gastric pentadecapeptide BPC 157 (GEPPPGKPADDAGLV) (for review, see Refs. [1][2][3][4][5][6][7][8][9][10][11][12] ). Previously, as an anti-ulcer peptide stable in human gastric juice [4][5][6][7][8][9] BPC 157 was effective in inflammatory bowel disease therapy (PL 14736) (no toxicology reported (for review, see Ref.…”

“…Also, BPC 157 particularly improved healing of transected tendon and muscle 1,2,10,11 and wound healing effect including the expression of the early growth response 1 (egr-1) gene (but also its repressor nerve growth factor 1-A binding protein-2 (nab2)). [4][5][6]9,10,12,13 Therefore, such peptide's capabilities [1][2][3][4][5][6][7][8][9][10][11][12] and responsibility for cytokine and growth factor generation and early extracellular matrix (collagen) formation may provide a peptide therapy effective functionally, biomechanically, macroscopically, and microscopically, [1][2][3][4][5][6]9,10,12,13 and thereby, suitable to improve ligament healing.…”